Technology areas: Biotechnology & Pharmaceuticals • Transportation, E-Commerce & Mechanical Systems
25 pending office actions • 14 art units • 20 examiners • 0 of 25 (0%) have an AI response strategy ready • 19 patents granted in the last 365 days
Tempus AI Inc. has 27 pending office actions in Biotechnology & Pharmaceuticals. The matters involve 22 distinct examiners and 15 distinct art units, indicating a portfolio distributed across multiple examination teams and technical classifications. Repeated examiner assignments exist, but the data does not identify a single dominant examination relationship.
SABOUR, GHAZAL is the busiest examiner, with 3 pending matters. That cluster is useful for targeted review of response strategy and prosecution history, while the broader examiner and art-unit distribution calls for consistent portfolio controls. Counsel should coordinate technical positions across related matters without assuming uniform examination treatment.
Based on the USPTO statutory response window for each pending office action. 8 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 8 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 only | 2 (8%) |
| §101 + other | 17 (68%) |
| §103 only | 4 (16%) |
| Double-patenting + other | 1 (4%) |
| Multi-statute (no §101) | 1 (4%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| SABOUR, GHAZAL | 3 | 34.2% | +35.0% |
| MINCHELLA, KAITLYN L | 3 | 26.4% | +21.7% |
| NEWTON, CHAD A | 2 | 38.4% | +23.4% |
| MOSER, BRUCE M | 1 | 84.2% | +20.1% |
| LAGOY, KYRA RAND | 1 | 9.5% | -11.1% |
| VARNDELL, ROSS E | 1 | 84.7% | +13.2% |
| HIGGS, STELLA EUN | 1 | 39.1% | +34.4% |
| GEDRA, OLIVIA ROSE | 1 | 8.3% | +24.0% |
| FEREJA, SAMUEL D | 1 | 75.0% | +10.1% |
| SMITH, KEVIN LEE | 1 | 36.8% | +18.5% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18398649 | SYSTEMS AND METHODS FOR PREDICTING PATIENT RECRUITMENT AT CLINICAL SITES | MERCHANT, SHAHID R | 111d overdue |
| 18635663 | SYSTEMS AND METHODS FOR PREDICTING CLINICAL RESPONSE | ILAGAN, VINCENT CAESAR | 99d overdue |
| 19210931 | CANCER TREATMENT EFFICACY EVALUATION UPON UNDERGOING OR COMPLETING A CANCER TREATMENT | SABOUR, GHAZAL | 58d overdue |
| 19067139 | ARTIFICIAL INTELLIGENCE ENGINE FOR DIRECTED HYPOTHESIS GENERATION AND RANKING | MOSER, BRUCE M | 19d overdue |
| 17548084 | Systems and Methods for Homogenization of Disparate Datasets | HAYES, JONATHAN EDWARD | 5d overdue |
| 18544092 | SYSTEMS, METHODS, AND ARTICLES FOR STRUCTURED ELECTRONIC HEALTH RECORD IMPUTATION USING DIAGNOSTIC TEMPORAL WINDOW | COVINGTON, AMANDA R | 7d |
| 18091320 | MULTIMODAL CARDIO DISEASE STATE PREDICTIONS COMBINING ELECTROCARDIOGRAM, ECHOCARDIOGRAM, CLINICAL AND DEMOGRAPHICAL INFORMATION RELATING TO A PATIENT | SHELDEN, BION A | 22d |
| 16732229 | TRANSCRIPTOME DECONVOLUTION OF METASTATIC TISSUE SAMPLES | MINCHELLA, KAITLYN L | 28d |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 19210931 | CANCER TREATMENT EFFICACY EVALUATION UPON UNDERGOING OR COMPLETING A CANCER TREATMENT | SABOUR, GHAZAL | 58d overdue |
| 19067139 | ARTIFICIAL INTELLIGENCE ENGINE FOR DIRECTED HYPOTHESIS GENERATION AND RANKING | MOSER, BRUCE M | 19d overdue |
| 16732229 | TRANSCRIPTOME DECONVOLUTION OF METASTATIC TISSUE SAMPLES | MINCHELLA, KAITLYN L | 28d |
| 19362140 | DATA BASED CANCER RESEARCH AND TREATMENT SYSTEMS AND METHODS | NEWTON, CHAD A | — |
| 18936982 | PREDICTING TOTAL NUCLEIC ACID YIELD AND DISSECTION BOUNDARIES FOR HISTOLOGY SLIDES | VARNDELL, ROSS E | — |
| 18913883 | SYSTEMS AND METHODS FOR MOLECULAR RESIDUAL DISEASE LIQUID BIOPSY ASSAY | SABOUR, GHAZAL | — |
| 18789091 | COMPUTER SYSTEMS FOR CHECK POINT IDENTIFICATION | HIGGS, STELLA EUN | — |
| 18782994 | SYSTEMS AND METHODS FOR PHENOTYPING USING LARGE LANGUAGE MODEL PROMPTING | GEDRA, OLIVIA ROSE | — |
| Art Unit | Apps |
|---|---|
| 1686 | 5 |
| 1685 | 4 |
| 3681 | 3 |
| 3685 | 2 |
| 3686 | 2 |
| 2154 | 1 |
| 2674 | 1 |
| 3600 | 1 |
| 2487 | 1 |
| 2122 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19362140 | DATA BASED CANCER RESEARCH AND TREATMENT SYSTEMS AND METHODS | NEWTON, CHAD A | 3681 | §103 | Final Rejection | — | Pending | Oct 17, 2025 |
| 19210931 | CANCER TREATMENT EFFICACY EVALUATION UPON UNDERGOING OR COMPLETING A CANCER TREATMENT | SABOUR, GHAZAL | 1686 | §101§103 | Final Rejection | 58d overdue | Pending | May 16, 2025 |
| 19067139 | ARTIFICIAL INTELLIGENCE ENGINE FOR DIRECTED HYPOTHESIS GENERATION AND RANKING | MOSER, BRUCE M | 2154 | §101§103 | Final Rejection | 19d overdue | Pending | Feb 28, 2025 |
| 19042728 | DETECTING CARDIOVASCULAR CONDITION FROM ELECTROCARDIOGRAM DATA USING ENSEMBLE OF ARTIFICIAL INTELLIGENCE MODELS | LAGOY, KYRA RAND | 3685 | §101§103 | Non-Final OA | — | Pending | Jan 31, 2025 |
| 18936982 | PREDICTING TOTAL NUCLEIC ACID YIELD AND DISSECTION BOUNDARIES FOR HISTOLOGY SLIDES | VARNDELL, ROSS E | 2674 | §103§112Other | Final Rejection | — | Pending | Nov 04, 2024 |
| 18913883 | SYSTEMS AND METHODS FOR MOLECULAR RESIDUAL DISEASE LIQUID BIOPSY ASSAY | SABOUR, GHAZAL | 1686 | §101§103 | Non-Final OA | — | Pending | Oct 11, 2024 |
| 18789091 | COMPUTER SYSTEMS FOR CHECK POINT IDENTIFICATION | HIGGS, STELLA EUN | 3681 | §101§103 | Final Rejection | — | Pending | Jul 30, 2024 |
| 18782994 | SYSTEMS AND METHODS FOR PHENOTYPING USING LARGE LANGUAGE MODEL PROMPTING | GEDRA, OLIVIA ROSE | 3600 | §101§103 | Non-Final OA | — | Pending | Jul 24, 2024 |
| 18679332 | Systems and Methods for Configuring a Task-Specific Machine-Learning Model at a Computer System | FEREJA, SAMUEL D | 2487 | §103 | Non-Final OA | — | Pending | May 30, 2024 |
| 18679368 | Systems and Methods for Generating Task-Specific Agent Modules Based on User Requests | SMITH, KEVIN LEE | 2122 | §101§102§103§112 | Non-Final OA | — | Pending | May 30, 2024 |
| 18660213 | DATA BASED CANCER RESEARCH AND TREATMENT SYSTEMS AND METHODS | NEWTON, CHAD A | 3681 | §101§102§103 | Final Rejection | — | Pending | May 09, 2024 |
| 18635663 | SYSTEMS AND METHODS FOR PREDICTING CLINICAL RESPONSE | ILAGAN, VINCENT CAESAR | 3686 | §101§103§112 | Final Rejection | 99d overdue | Pending | Apr 15, 2024 |
| 18592272 | SYSTEMS AND METHODS FOR GENERATING A RADIOLOGY REPORT | NGUYEN, PHU K | 2616 | §103 | Final Rejection | — | Pending | Feb 29, 2024 |
| 18398649 | SYSTEMS AND METHODS FOR PREDICTING PATIENT RECRUITMENT AT CLINICAL SITES | MERCHANT, SHAHID R | 3684 | §101 | Non-Final OA | 111d overdue | Pending | Dec 28, 2023 |
| 18544092 | SYSTEMS, METHODS, AND ARTICLES FOR STRUCTURED ELECTRONIC HEALTH RECORD IMPUTATION USING DIAGNOSTIC TEMPORAL WINDOW | COVINGTON, AMANDA R | 3686 | §101 | Non-Final OA | 7d | Pending | Dec 18, 2023 |
| 18210449 | SYSTEMS AND METHODS FOR GENERATING HISTOLOGY IMAGE TRAINING DATASETS FOR MACHINE LEARNING MODELS | CLOW, LORI A | 1671 | §101§102§103DP | Non-Final OA | — | Pending | Jun 15, 2023 |
| 18298371 | DATA BASED CANCER RESEARCH AND TREATMENT SYSTEMS AND METHODS | SABOUR, GHAZAL | 1686 | §101§103§112DP | Non-Final OA | — | Pending | Apr 11, 2023 |
| 18176476 | Systems and Methods for Detecting Cellular Pathway Dysregulation in Cancer Specimens | DARRIGRAND, EMILY ANN | 1686 | §101§102§103 | Non-Final OA | — | Pending | Feb 28, 2023 |
| 18091320 | MULTIMODAL CARDIO DISEASE STATE PREDICTIONS COMBINING ELECTROCARDIOGRAM, ECHOCARDIOGRAM, CLINICAL AND DEMOGRAPHICAL INFORMATION RELATING TO A PATIENT | SHELDEN, BION A | 3685 | §101§103§112 | Final Rejection | 22d | Pending | Dec 29, 2022 |
| 17963969 | METHODS AND SYSTEMS FOR DETECTING ALTERNATIVE SPLICING IN SEQUENCING DATA | RIGGS II, LARRY D | 1686 | §101§103§112 | Non-Final OA | — | Pending | Oct 11, 2022 |
| 17857901 | LARGE SCALE ORGANOID ANALYSIS | NGUYEN, NAM P | 1678 | §103DP | Non-Final OA | — | Pending | Jul 05, 2022 |
| 17571412 | SYSTEMS AND METHODS FOR JOINT LOW-COVERAGE WHOLE GENOME SEQUENCING AND WHOLE EXOME SEQUENCING INFERENCE OF COPY NUMBER VARIATION FOR CLINICAL DIAGNOSTICS | MINCHELLA, KAITLYN L | 1685 | §103 | Final Rejection | — | Pending | Jan 07, 2022 |
| 17548084 | Systems and Methods for Homogenization of Disparate Datasets | HAYES, JONATHAN EDWARD | 1685 | §101§103§112 | Final Rejection | 5d overdue | Pending | Dec 10, 2021 |
| 17150992 | SYSTEMS AND METHODS FOR MULTI-LABEL CANCER CLASSIFICATION | MINCHELLA, KAITLYN L | 1685 | §101§103 | Final Rejection | — | Pending | Jan 15, 2021 |
| 16732229 | TRANSCRIPTOME DECONVOLUTION OF METASTATIC TISSUE SAMPLES | MINCHELLA, KAITLYN L | 1685 | §101§103 | Final Rejection | 28d | Pending | Dec 31, 2019 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialTempus AI Inc. has 25 pending office actions as of October 2026, spread across 14 art units and 20 examiners.
Ghazal Sabour has the most, with 3 of Tempus AI Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
